Celularity Inc (NASDAQ: CELU)

Celularity Inc is a regenerative and cellular medicines company focused on aging related and degenerative diseases.

The company leverages the placenta’s biology to develop biomaterials and cell therapy product candidates.

It sells advanced biomaterial products such as Biovance 3L and Rebound directly and through distributors.

Celularity also develops off the shelf placental derived allogeneic cell therapy candidates including mesenchymal like adherent stromal cells and natural killer cells.

In addition the company provides contract manufacturing and development services to third party cell therapy firms and operates a commercial biobanking service for expectant parents.

Celularity generates revenue primarily from the sale of its advanced biomaterial products including Biovance 3L Rebound and related lines.

The company also earns fees from contract manufacturing and development services provided to other biopharmaceutical entities.

Additionally the biobanking business contributes revenue through upfront collection and processing fees and recurring storage fees paid by customers.

Licensing arrangements and collaborations may provide further income but represent a smaller portion of total revenue.

The company operates through the following segments: Advanced Biomaterial Products and Biobanking.

• The Advanced Biomaterial Products segment focuses on the development manufacture and sale of placenta derived allografts and connective tissue matrices for soft tissue repair and reconstructive procedures. Key products include Biovance 3L Rebound Interfyl CentaFlex and investigational items such as the Celularity Tendon Wrap the Bone Void Filler and the Placental Matrix.

• The Biobanking segment involves the collection processing and cryogenic storage of birth related materials such as umbilical cord blood and placenta derived cells and tissue for expectant parents. Customers pay an initial fee for collection processing and preservation and an annual storage fee over a typical term of eighteen to twenty five years.

Celularity occupies a niche in the regenerative medicine field by combining a proprietary placenta sourcing and manufacturing platform with a broad intellectual property portfolio.

Competitors in the cell therapy space include Allogene Therapeutics Atara Biotherapeutics Fate Therapeutics CRISPR Therapeutics and Mesoblast.

In the biomaterials arena the company faces competition from Mimedx Organogenesis and other established tissue based product providers.

Celularity’s advantages stem from its ability to produce off the shelf allogeneic products at scale its integrated manufacturing system and its extensive patent estate covering over two hundred ninety filings related to its core technologies.

The company serves hospitals ambulatory surgery centers wound care clinics and orthopedic practices through its distribution network.

Specific partners include Arthrex which distributes Biovance Interfyl and CentaFlex in the United States and BioCellgraft which private labels Celularity biomaterials for dental and oral health applications.

The biobanking business sells directly to expectant parents who contract for the preservation of newborn tissue.

Additionally Celularity provides contract manufacturing services to early stage cell therapy companies seeking outsourced development and production support.